Company intelligence / Profile preview

Genova Biotechnology

Hangzhou, Zhejiang, China

Ownership: Private
Development stage: Other

Overview

Genova Biotechnology is a Chinese biopharmaceutical company focused on the development and commercialization of high-quality biologics and biosimilars. The company primarily targets therapeutic areas such as ophthalmology, oncology, and autoimmune diseases, with a significant emphasis on anti-VEGF therapies for retinal disorders. Genova operates integrated research, development, and manufacturing facilities designed to meet international standards, aiming to provide affordable biological treatments to the global market. Their lead programs include biosimilar versions of blockbuster drugs like ranibizumab and adalimumab.

Therapeutic areas: OncologyImmunologyOphthalmologyDermatology
Modalities: Monoclonal antibodyRecombinant proteinBiosimilar
Industry: Biotech

Beyond the preview

Go deeper on Genova Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Genova Biotechnology.

Explore the full profile